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Abstract 
Background Metabolomics refers to study of the metabolome, the entire set of 
metabolites produced by a biological system. The application of metabolomics to exhaled 
breath samples - breathomics - is a rapidly growing field with potential application to 
asthma diagnosis and management.   
Objectives We aimed to review the adult asthma breathomic literature and present a 
comprehensive list of volatile organic compounds identified by asthma breathomic 
models.  
Methods We undertook a systematic search for literature on exhaled volatile organic 
compounds in adult asthma. We assessed the quality of studies and performed a 
qualitative synthesis.   
Results We identified twenty studies; these were methodologically heterogenous with a 
variable risk of bias. Studies almost universally reported breathomics to be capable of 
differentiating - with moderate or greater accuracy - between samples from healthy 
controls and those with asthma; and to be capable of phenotyping disease. However, 
there was little concordance in the compounds upon which discriminatory models were 




Conclusion Results to-date are promising but validation in independent prospective 
cohorts is needed. This may be challenging given the high levels of inter-individual 
variation. However, large-scale, multi-centre studies are underway and validation efforts 
have been aided by the publication of technical standards likely to increase inter-study 
comparability. Successful validation of breathomic models for diagnosis and phenotyping 
would constitute an important step towards personalised medicine in asthma. 
1. Introduction 
 
Asthma is a chronic disorder of the airways characterised by variable airflow obstruction 
commonly accompanied by inflammation. It is affects an estimated 339 million people 
worldwide (1), and generates a health service spending of approximately £1 billion per 
annum in the UK alone (2). Management of the condition is informed chiefly by 
symptoms and measures of airway calibre such as peak expiratory flow. 
The identification and or quantification of metabolites offers an alternative route to 
diagnosis and disease management. Metabolites are low molecular weight (typically 
defined as <1500 amu1) organic and inorganic chemicals produced by cellular processes 
(including pathophysiological processes). The term ‘metabolome’ refers to the entire set 
of metabolites associated with a biological system(3). Change in the metabolome reflects 
change in underlying cellular activity(4) - disease pathophysiology can alter the relative 
concentrations of metabolites produced, or produce metabolites which are absent in 
health(5) - metabolomics is thus gaining traction as a means of biomarker discovery in 
disease(6). 
Volatile organic compounds (VOCs) are carbon-based, low molecular weight compounds, 
volatile at room temperature. The study of endogenous VOCs generated by metabolic 
processes within the body and exhaled on the breath is commonly referred to as 
breathomics (7). Such studies produce data on a large number of compounds permitting 
inductive, hypothesis-generating approaches in which data are interrogated in order to 
identify disease-induced metabolomic permutations(8) without the prior identification of 
a candidate marker. This approach has been applied to many diseases including asthma. 
Rufo et al (9) conducted a systematic review of the asthma breathomic literature in 2014, 
identifying 18 studies which reported on diagnostic accuracy. In a meta-analysis of six 
studies they calculated a pooled area-under-the-curve (AUC) value of 0.94. This figure 
needs to be interpreted with caution however as all but one of the included studies 
compared established-treated disease with non-disease (rather than testing diagnostic 
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accuracy in those with a suspicion of disease) and the meta-analysis pooled diagnostic 
models which were comprised of differing VOCs. In addition, a mixture of adult and 
paediatric studies were included; age has since been identified as a factor which should 
be controlled for (10).  
Interest in the field has continued to grow and a number of breathomic asthma studies 
have since been published. Neerincx et al (11) reviewed paediatric asthma breathomics, 
to which a systematic search has been appended (12); and recent reviews have provided 
an overview of metabolomics in exhaled breath (13) and across different biomediums 
(14, 15). In this study we aim to systematically review the literature on adult asthma 
breathomics - including studies of diagnosis and of disease characteristics - providing a 
comprehensive list of significant VOCs identified to-date.  
2. Methods  
 
A study protocol was developed in line with Prisma-P guidelines and registered with the 
International Prospective Register of Systematic Reviews (PROSPERO) (registration 
number CRD42017082727).  The primary objective of the review was to ascertain the 
classification accuracy of VOC models for asthma diagnosis, phenotyping, and disease 
control. The secondary objectives were to identify the study methods used and to 
compile a list of those VOCs identified by studies as significant for use in future 
validation efforts. 




The following key words and MeSH terms were used - metabolomics, breathomics, 
exhaled breath, breath test, volatile organic compound* and asthma. The search 
string was optimised for each database; an example may be found in the appendix. 
 
SEARCH STRATEGY 
Inclusion criteria – Physician diagnosed asthma or asthma diagnosis according to 
recognised guidelines; clinical studies published in full; primary data; VOCs in exhaled 
breath studied (by any collection or analytical method). 
Exclusion – Reviews; editorial; secondary data; studies of exhaled breath condensate; 






PubMed; Medline (including Embase and OVID medline) 
In addition, the references from Rufo et al’s review; from the researchers’ own 
reference libraries; and from the reference lists of included articles were searched. 
Researchers working in the field were asked to highlight papers they were aware of.  
The searches were conducted independently by two reviewers (AS and AP) on the 1st 
June 2017 and updated in November 2018. 
 
Two reviewers (AP & AS) screened titles and abstracts for inclusion, resolving 
discrepancies through discussion with a third reviewer (MW). In total two hundred and 
ninety records were identified; this was reduced to two hundred and sixty six after 
removing duplicates. On screening abstracts and/or full texts, forty eight citations of 
adult asthma breathomic studies were identified, of which twenty eight were abstracts 
and twenty full journal articles. A PRISMA diagram (figure 1) describes the screening and 
selection process. Quality assessment was undertaken using the CASP diagnostic 
checklist (16) (see appendix table A4). Data extraction and quality assessment was 
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 Additional records identified 
through other sources 
(n = 8) 
Records after duplicates removed 
(n = 266) 
Records screened 
(n = 266) 
Records excluded 





Reasons for exclusion – 
disease other than 
asthma, not primary data, 
EBC not VOCs 
Abstracts or full-text 
articles assessed for 
eligibility 
(n = 78) 
Articles excluded  
(n = 30) 
 
Paediatric asthma (n=17) 
EBC not VOCs (n=5) 
In vitro study (n=1) 
Not asthma (n=1) 
Mixed asthma/COPD 
population (n=1) 
Mixed age population 
(n=2) 
No VOC results presented 
(n=3) 
Adult asthma breathomic 
references identified 
(n = 48) 
Studies published in full 
(n = 20) 
Abstracts  






Twenty journal articles met the criteria for inclusion (table 1). Fifteen of these compared 
VOCs in asthma and healthy controls (17-30), of which ten reported diagnostic accuracy 
(18-20, 22, 23, 26-30). Four studies reported on the ability to differentiate between 
asthma and COPD, one lung cancer and one allergic rhinitis (19, 28-31). Seven studies 
examined the ability to discriminate between phenotypes (18, 20, 26, 31-34) (two were 
cluster analyses), while three reported on levels of disease control or activity (20, 24, 
32).  
We included one paper (35) which failed to meet Rufo et al’s inclusion criteria (due to 
the absence of a comparator group) and excluded one (36) which used exhaled breath 
condensate as its sample medium. We included one paper (17) reporting on volatile 
organosulfides and excluded one study which recruited both adults and adolescents (37, 
38). 
Results were typically given as accuracy rates for the correct classification of samples - 
the area under the curve for receiver operator characteristics (AUROC), cross-validation 
values (CVV) or correlation coefficients. Table 1 displays the list of full publications along 
with results; Table A2 (appendix) summarises study design and breath sampling 
methods; while Table A3 (appendix) details the data processing and statistical methods 
used. There was heterogeneity in all aspects of study methodology, from sample 
collection through to statistical analysis. The majority of GC-MS studies used principal 
component analysis (PCA) in their statistical analysis however approaches to data pre-
processing, discriminatory analysis and cross-validation varied. Given the methodological 
heterogeneity and variety of compounds upon which breathomic models were based, 






Table 1 – Included studies and results 
Study Country Year Population Result 
Awano et al  
(17) 
Japan 2011 Asthma = 7 
Non-asthma = 386 
(both groups age range 60-65) 
Asthma and the presence of dimethyl sulphide > 1.0nmol L-1   in mouth air 
Crude OR 7.4 (95%CI 1.4-39.0); Adjusted OR 6.9 (95% CI 1.1-44.2) 
Brinkman et 
al (32)  
Netherlands 2017 Asthma (partly controlled, mild-
moderate) = 23 
Baseline vs loss of control: eNose classification accuracy - 95%, GC-MS 68% 
Loss of control vs recovery: eNose classification accuracy - 86%, GC-MS 77% 
Significant association between exhaled metabolites and sputum eosinophils: Pearson 
r>0.46, P<0.01 
Dragonieri 
et al (18) 
Netherlands 
 
2007 Asthma (mild-severe)  
= 20 
Controls = 20 
Asthma vs controls:  CVV 90-100%; M-distance 2.77-5.32. 
Mild vs severe asthma: CVV 65%; M-distance, 1.23. 
Dragonieri 
et al (30) 
Italy 2018 Asthma & allergic rhinitis (AAR): 
training set = 14; validation set = 7. 
Allergic rhinitis only (AR) and 
healthy controls (HC) as above 
Training set  
AAR vs AR: CVA=86%, p<0.01; AUROC 0.93  
AR vs HC: CVA=82%, p<0.01; AUROC 0.92 
AAR vs HC: CVA=75% ,p<0.05; AUROC 0.87  
Validation set 
AAR vs AR: CVA=83%, p<0.01; AUROC 0.92  
AR vs HC: CVA=77%, p<0.01; AUROC 0.87 
AAR vs HC: CVA=67 , p<0.05; AUROC 0.77 
Fens et al 
(19)  
Netherlands 2009 Asthma (mild-severe, persistent) = 
20 
COPD = 30 
Controls = 40 
Asthma vs COPD: accuracy 96%; p< 0.001 
Asthma vs controls: accuracy 93 – 95%; p< 0.001 
Fens et al 
(31)       
Netherlands 2011 Asthma (stable) = 60  
(21 w/ fixed airways) 
COPD = 40 
Asthma vs COPD: accuracy 83-88%; p<0.001 
AUROC 0.93-95 (95% CI 0.84–1.00); sensitivity 85-91%, specificity 90% 
Fixed asthma vs classic asthma: accuracy 58%; p=0.23; AUROC 0.68 (95% CI 0.50-0.85); 
sensitivity 60%, specificity 67%. 
Ibrahim et 
al  (20) 
UK 2011 Asthma (mild-moderate) = 35 
(sputum for phenotyping n=18) 
Controls = 23 
 
Asthma vs controls: accuracy = 86% (PPV 0.85, NPV 0.89) 
Sputum eosinophilia: AUROC 0.98 (95% CI = 0.91-1.00; sensitivity = 0.75, specificity = 0.90). 
Sputum neutrophilia: AUROC 0.90 (95% CI = 0.76-1.00; sensitivity = 0.80, specificity = 0.75). 




Larstad et al 
(21) 
Sweden 2007 Asthma (stable) = 13 
Controls = 14 
Baseline isoprene lower in asthmatic subjects (113 ppb vs 143; p = 0.03) 
No significant difference in baseline ethane, pentane, or nitric oxide. 




2010 Asthma (stable) = 10 Reduction in airway calibre was not associated with an altered eNose breath profile 
Meyer et al 
(22) 
Switzerland 2014 Asthma (mixed severity) = 195 
Controls = 40 
Asthma vs controls: accuracy 99% (sensitivity 100%, specificity 91%) 
Inter-cluster or cluster vs control accuracy: 82% – 95% 
Linear discriminant analysis for correct classification of all clusters and controls = 43%. 
Montuschi 
et al (23) 
Italy 2010 Asthma (mild, intermittent) = 27 
Controls = 24 
Asthma vs controls: diagnostic accuracy 88% 
 
Olopade et 
al (24)  
USA 1997 Asthma (acute exacerbation) = 12 
Stable asthma  = 11 
Controls = 17 
Significantly higher exhaled pentane levels during acute exacerbation (p < 0.05). No 
significant difference in exhaled pentane levels between stable/controlled asthma and 
healthy controls (P>0.05). 
Paredi et al 
(25) 
UK 2000 Asthma (steroid naive) = 14 
Asthma (steroid treated) = 12 
Controls = 14 
Ethane in untreated asthmatics > healthy controls or ICS treated asthma (p<0.05) 
In untreated asthma, exhaled ethane correlated with levels of nitric oxide exhalation 
(p<0.05); those with FEV1 <60% predicted had higher levels of ethane than those >60% 
(p<0.05). 
Plaza et al  
(33) 
Spain 2015 Asthma (persistent) = 52 Eosinophilic vs neutrophilic: accuracy 73%; P=0.008; AUROC 0.92 
Eosinophilic vs paucigranulocytic: accuracy 74%; P=0.004; AUROC 0.79 
Neutrophilic vs paucigranulocytic: accuracy 89%; P=0.001; AUROC 0.88 
Reynolds et 
al (35)  
UK 2014 Asthma & controls = 17 
 
Discriminant analysis of asthma vs controls not reported 
van der 




2013 Asthma (mild-moderate) = 25  
Controls = 20 
Asthma vs controls: AUROC 0.77 (95%CI = + 0.14; P = 0.002) 
Steroid responsiveness: AUROC = 0.88 (95% CI = + 0.16; P = 0.008) 
van der 
Schee et al 
(27) 
Europe 2013 Asthma (U-BIOPRED, severity not 
specified) = 10 
Controls = 10 
Asthma vs control:  
eNose AUROC = 0.77 (95% CI = 0.22), p = 0.050 




Australia 2012 Asthma (GINA step 1-3) = 20 
COPD = 17 
Controls = 7 
Asthma vs controls: eNose accuracy 70%, p=0.047 




de Vries et 
al (29) 
Netherlands 2015 Asthma (mild to severe) = 37 
Controls = 45 
COPD = 31 
Lung cancer = 31 
Asthma vs COPD: accuracy 81%, AUROC 0.81 (95%CI + 0.09), p=0.001 
Asthma vs controls: accuracy 87%, AUROC 0.94 (95%CI + 0.15), p<0.001 
Asthma vs lung cancer: accuracy 68%, AUROC 0.71 (95%CI + 0.09), p=0.045 
 
de Vries et 
al (34) 
Netherlands 2018 Asthma (mild to severe)= 278  
COPD = 157. 
Training set=321; validation set 
114. 
Training set 
Clusters differing in ethnicity (p=0.01); systemic eosinophilia (p=0.02); neutrophilia(p=0.03); 
BMI (p=0.04);  FeNO (p<0.01),  atopy (p<0.01); exacerbation rate(p<0.01). Regression models 
predictive of eosinophilia (R2=0.58); neutrophilia (R2=0.41)  
Validation set 





AUROC – area under the curve for receiver operator characteristics 
CVA – cross-validation accuracy 
CVV – cross-validation value 
NPV – negative predictive value (percentage of true negatives)                                 
PPV – positive predictive value (percentage of true positives) 




3.1 Quality assessment 
We excluded studies published only in abstract form due to the inability to fully assess 
inclusion criteria, study quality and risk of bias. However, the exclusion of such 
publications creates a vulnerability to selective dissemination bias. Results from these 
abstracts can be found in table A4 (appendix).  
Twenty studies were published in full and their quality assessed using the CASP checklist 
(see table A5, appendix). 
Examining predictive models for their diagnostic test accuracy in asthma, there is no 
single valid and reliable test against which the new diagnostic can be measured. In a 
recent study of patients with a primary care diagnosis of asthma (40) the diagnosis could 
not be supported in 33% of cases; furthermore this is not a novel finding (41-43). The 
matter is further complicated by the heterogenous nature of the disease; inflammation is 
not an essential component of the disease, thereby limiting the use of existing 
inflammatory biomarkers. We included studies with diagnoses made by a physician or 
according to recognised clinical guidelines while accepting that, as a reference standard, 
this is likely to fall short of the assumed 100% accuracy. One study recruited from a 
severe asthma clinic with physician diagnosis inferred rather than explicitly stated (35).  
Studies of diagnostic test accuracy should ideally examine the population in which the 
test would be employed - those with a clinical suspicion of disease or diagnostic 
uncertainty. The majority of studies compared healthy controls against participants with 
an existing asthma diagnosis (and commonly receiving treatment); such results are 
likely to over-estimate diagnostic accuracy and might perhaps better be characterised as 
hypothesis-generating or proof-of concept studies. In the majority of studies it was not 
clear that a random or continuous sample of patients had been used; where there is 
selection of participants there is risk of inclusion bias leading to over-estimation of test 
accuracy.  
For those studies reporting on the occurrence of symptoms or loss of asthma control, the 
time between symptom reporting and VOC-sampling is important. The inherent 
variability of the disease and potential for symptoms to change means that any delay 
between reporting and measuring could lead to inaccuracy or obfuscate a relationship. 
Furthermore factors such as the time of day should be considered as asthma is a 
circadian disease and related VOCs display diurnal variation (44). Timing in studies was 
frequently implied rather than explicitly stated.  
In the majority of studies it was not possible to say that index tests were conducted and 
interpreted without knowledge of the reference standard; blinding was rarely mentioned. 




mass spectrometry, and statistical methods such as PCA are hard to corrupt. Some risk 
nevertheless exists as storage time and conditions prior to processing have the potential 
to influence outcomes; in addition statistical methods for discriminant analysis are prone 
to over-fitting and require validation 
Study participants were generally well described with the exception of body mass index 
(BMI) and ethnicity. BMI may affect markers of oxidative stress (45) and VOCs (10, 34); 
and evidence exists of ethnic differences in both pulmonary function (46, 47) and breath 
profiles (34, 48).  
3.1.1 Technical validity 
 
3.1.1.1 Breath sampling 
There are two key methodological issues relating to sample collection a) that of how to 
best deal with ambient VOCs; and b) how to collect and store samples prior to analysis. 
Ambient VOCs 
A consensus method for dealing with ambient, environmental VOCs has been outlined by 
European Respiratory Society (ERS) technical standards (49). This recommends 1) 
parallel sampling of ambient air for background correction using alveolar concentration 
gradients, and 2) the use of VOC-filtered air. More detailed discussion of these issues 
can be found within the technical standards themselves (50). Of the included studies, 
ten measured ambient air VOCs; the way these data were utilised varied. 
Exogenous VOCs in breath can be minimised through the use of filtered air but inhaled 
VOCs may be retained for some time and wash-out periods vary depending on the VOC 
in question. Wallace et al (51) estimate that some retention times may be as long as 3 
days; and breathing synthetic air for 30 minutes was found to reduce but not eliminate 
ambient VOCs (52). If VOC analysis is to be clinically useful the period of time for which 
filtered air is breathed prior to assessment needs to be practicable; complete elimination 
of the ‘exposome’ is unlikely. Furthermore, ambient VOCs may be absorbed 
transdermally. In the case of some semi-volatile or aerosolised compounds, dermal 
uptake may be up to four times higher than inhalation (53, 54) however the relationship 
between dermally absorbed VOCs and their exhalation is largely unstudied. Current 
recommendations offer a pragmatic rather than a perfect solution; twelve of the included 
studies used filtered air.   
Sampling methods 
Two main approaches have been taken to the collection of samples prior to analysis – 1) 




Numerous studies have examined the properties of gas sampling bags (55-59). 
Beauchamp et al (58) summarise the drawbacks of this method which include material 
emissions, diffusion of VOCs (into or out of the bag), adsorption effects, reactive 
chemistry and the production of artefacts. While VOC losses have been described as 
within acceptable levels (57, 58) this could nonetheless result in those VOCs present at 
very low concentrations becoming undetectable; moreover the differential decay rates 
reported across VOCs could change relative concentrations over time.  
Breath samples collected in impermeable bags can be concentrated using stainless steel 
tubes packed with adsorbent material. These may be stored (60, 61) before desorption 
and analysis; studies suggest storage at room temperature for fourteen days or less 
results in acceptable sample retention (27). Direct sampling onto sorbents is also 
possible. In both cases a decision has to be made as to which adsorbent(s) to use. Tenax 
– a porous polymer - is used in many of the studies; its hydrophobicity is suited to 
humid breath samples and it can adsorb a wide range of VOCs (62). Its ability to capture 
low mass VOCs is however limited and compound breakthrough may be an issue. Dual-
bed sorbents are an attempt to combat these issues while also limiting the quantity of 
water adsorbed. If a deductive approach is used - looking for specific compounds - the 
appropriate sorbent(s) need to be selected. For inductive approaches there must be 
recognition that sorbent selection limits the range of VOCs collected; disease-related 
VOC permutations may go undetected if outside of this range. The stability of adsorbed 
samples is time and temperature dependant (63) ; of the six studies concentrating 
samples on sorbent tubes, two did not report the duration of storage, and three either 
did not report the temperature or stored samples at room temperature.  
In addition to the storage of samples there is also variation in the nature of the sample. 
The majority of included studies using Tedlar bags collected mixed expiratory air by way 
of single or multiple exhalations. However, if the lung metabolome is the exclusive target 
of investigation there will be sample contamination from the upper respiratory tract. The 
importance of breath fraction to asthma breathomics is yet to be established. It is 
possible to quantify breath samples either by collection time or volume but a standard 
approach to this has yet to be established (49).  
Ibrahim et al (20) used a novel device with a facemask and pressure sensor to 
selectively sample air from the lower respiratory tract directly onto sorbent tubes. This 
approach has since been commercialised in a device from Owlstone (Cambridge, UK). 
Fifteen of the studies used a collapsible reservoir (Tedlar or Nalophan bag) while one 




3.1.1.2 Sample analysis  
A range of methods have been applied to the analysis of breath samples including 
various forms of mass spectrometry; some offline - such as gas chromatography-mass 
spectrometry (GC-MS) - and others online - such as ion mobility spectrometry (IMS), 
proton transfer mass spectrometry (PTR-MS), selected ion flow tube mass spectrometry 
(SIFT-MS) and  field asymmetric ion mobility spectrometry (FAIMS). A full review of 
these methods may be found in Beale et al (62) and elsewhere. 
 
Due to its sensitivity and selectivity, GC-MS has become the standard method by which 
to characterise the human metabolome (64), including that detectable via the breath 
(60) (although alternatives such as FAIMS may be equally efficacious(65)). GC-MS 
analysis requires a high level of technical expertise and the data produced needs 
extensive pre-processing prior to statistical analysis. This approach has been 
complemented by the electronic nose (eNose); chemical cross-reactive sensor arrays 
(66) over which breath samples may be passed inducing detectable changes in the 
sensor material, thereby characterising the relative concentrations of VOCs present (67). 
eNoses lack the ability of MS to identify VOCs - thereby precluding their use for 
biomarker discovery - but require less data pre-processing; less technical expertise; 
and their ability to produce real-time data holds promise in point-of-care diagnostics 
(see table 2).  
 
Table 2 - eNose vs GC-MS 
 eNose GC-MS 
Approach Pattern recognition Compound identification 




Real time use Yes No 
Physical size Small, portable Large, immovable 
Data pre-processing required Some Extensive 
Technical expertise required 
for sample analysis 
No Yes 
 
Of the studies in this review, nine used an eNose; seven mass spectrometry; and four a 
combination of the two.  
 
3.1.2 Statistical validity 
 
A range of statistical techniques may be used in the identification of disease-induced 




13, 62). Although strategies for avoiding false discoveries (68) and minimum reporting 
standards for data analysis in metabolomics (69) have been published, there is no 
standard statistical framework for analyses (70); the ERS technical standards are not 
prescriptive in this respect. As shown in table A5, approaches to data processing and 
pre-processing varied, both in the techniques used and the extent to which they were 
reported.  
The majority of papers undertook inductive / untargeted analyses in which there was no 
a priori identification of compounds. Such analyses when applied to large data sets are 
prone to over-fitting and the resultant VOC models require validation; without this the 
performance of the model cannot purport to be accurate. Internal cross-validation is one 
of the methods commonly applied however the rigour this imparts may be limited by the 
small sample size of many of the included studies. Ten studies describe undertaking 
some form of internal validation such as leave one out cross-validation or boot strapping; 
only three studies used an external validation set (30, 31, 34). 
Five studies (17, 21, 24, 25, 27) conducted targeted analyses based on compounds 
previous identified as associated with asthma or inflammation; a deductive approach not 
associated with the aforementioned statistical challenges. Although these findings 
provide support for the utility of certain VOCs in asthma breathomics, they were not an 
attempt to provide external validation to any one specific model. Furthermore, although 
Awano et al (17) specified compounds of interest a priori, their relationship with clinical 
variables (including asthma) was examined by way of post-hoc analyses and vulnerable 
to the risk of false discovery.  
In studies other than those using an eNose, compound identification is possible. There 
are a number of databases which may be used including the Pacific Northwest National 
Laboratory (PNNL), the National Institute for Standards and Technology (NIST), Metlin, 
or in-house custom libraries constructed using reference standards. The extent to which 
use of different libraries might limit comparability is unclear; however, Sharpe et al (71) 
compared PNNL with NIST and reported that for all but one of the twelve compounds 
they compared, there was agreement between databases to within the level of 
experimental uncertainty. Few papers reported the libraries used for compound 
identification and none the match-percentages for compound identification. The chemical 
analysis working group metabolomics standards initiative (MSI) published proposed 
minimum reporting standards which include both data pre-processing and metabolite 
identification (72). Implementation of such reporting standards would allow identification 




3.1.3 Clinical validity 
Two potential confounders were common across studies – medication and study location. 
Participants with asthma were frequently taking medication such as inhaled 
corticosteroids (ICS) or β2-agonists which healthy controls were not; any observed 
between-group difference in exhaled VOCs might be due to medication metabolites 
rather than disease-related changes in biochemical pathways. The extent to which this 
was addressed in studies varied, likely due to the emergent nature of this field of 
research and the inclusion of small-scale, proof-of-concept studies. Evidence regarding 
the extent to which medication might act as a confounder is unclear (18, 26, 45, 73) but 
exhaled VOCs have been reported to be capable of identifying those asthma patients in 
which oral corticosteroid and salbutamol urinary metabolites were present (74).  
The second potential confounder was background bias. In many studies the site of 
recruitment differed between controls and those with asthma but it was unclear where 
breath sampling took place. de Vries et al (29) report no significant difference between 
samples from different medical sites (p=0.89); however the ambient VOC profile of 
hospitals may differ greatly from other locations (75) and a systematic difference in 
location could be the cause of sample differentiation, rather than disease metabolites. 
The application of background air subtraction and use of filtered air constitute an 
attempt to negate this but as discussed in section 3.1.2.1 there are limitations. 
 Other potential confounders such as smoking history, age, and gender (45) were not 
always well matched between groups (see table 2).  
Asthma severity was frequently stated but where it was not, medication-use was rarely 
reported with sufficient detail to make an assessment of severity. Many studies 
contained a mixture of asthma severities; and while spirometry results were commonly 
presented measures of asthma control were not. 
3.2 Qualitative synthesis 
 
3.2.1 Asthma Diagnosis   
The ability of breathomics to differentiate between those with asthma and healthy 
controls was examined by fifteen studies. These models reported moderate-to-excellent 
discriminative ability, citing CVVs of 90-100% (18), classification accuracies of 86%(20) 
to 99%(22), and AUROCs of between 0.70 (28) and 0.94 (29). It should be emphasised 
that these accuracy rates are based on populations with diagnosed disease; the studies 
were examining the difference in VOC profiles between healthy controls and those with 




of VOC models in a real clinical population with undiagnosed, untreated respiratory 
symptoms of relatively recent onset may be very different.  
In many studies the risk of sampling bias was unclear; and in some studies there was a 
risk of confounding, for example large differences in the average age of groups (26, 29). 
While we included studies with physician diagnosed asthma the standard to which this 
was reported and conducted varied between studies. It is also worth noting that several 
studies used populations of mixed asthma severity; it is unlikely that breathomic models 
would be applied homogenously across such a population. 
Five studies conducted a targeted analysis of compounds. In the case of pentane, 
Olopade et al (24) report significantly higher levels during acute asthma attack but both 
Olopade and Larstad et al (21) report no significant difference between controlled-
asthma and healthy controls. Paredi et al (25) report significantly higher levels of ethane 
in untreated asthma compared with treated disease or healthy controls. They do not 
comment on treated-asthma versus healthy controls but Larstad et al (21) found no 
significant difference (in ethane levels) between a largely steroid-treated controlled 
asthma group and healthy controls.  Larstad et al do however report a significantly lower 
level of isoprene in those with asthma. Awano et al cite an adjusted odds ratio of 6.9 (95% 
CI 1.1-44.2; p<0.05) for asthma in the presence of dimethyl sulphide; while van der 
Schee report AUCs of 0.79-0.84 (p<0.05) for the differentiation of asthma from controls 
using a five-compound model.  
Ten studies performed untargeted analyses producing diagnostic models for the 
differentiation of asthma from healthy controls. Fewer studies aimed to differentiate 
between asthma and other respiratory diseases; four examined COPD and asthma 
reporting classification accuracies of between 70% and 96% (19, 28, 29, 31); one  
differentiated between asthma and allergic rhinitis reporting an AUROC of 93% (30); 
while another examined lung cancer and asthma, reporting a classification accuracy 68% 
(29). In all but the allergic rhinitis study there was a large difference in average age 
between the asthma and the other respiratory disease group. 
3.2.2 Asthma Phenotypes   
Eight studies examined asthma phenotypes including sputum cell type, steroid 
responsiveness, disease severity and airway reversibility. 
Both Plaza et al (33) and Ibrahim et al (20) constructed models differentiating between 
eosinophilic, neutrophilic and paucigranulocytic phenotypes, with classification accuracies 
of 73% to 74% (33), and AUROCs of 0.79 (33) to 0.98 (20). Differentiation was likely 
not due to differences in ICS use (which were similar between groups in Plaza et al), but 




treatment regime. Brinkman et al report two VOCs significantly correlated with sputum 
eosinophilia (correlation coefficients of r>0.46 & 0.47 (P<0.01)) but did not find any 
such correlations for sputum neutrophilia (32). 
de Vries et al (34) examined a combined asthma and COPD population in a large multi-
centre study. They identified clusters differing in eosinophilia (p=0.02), neutrophilia 
(p=0.03), atopy (p<0.01) and exacerbation rate (p<0.01). Further clusters based on 
ethnicity (p=0.01) and exhaled nitric oxide (p<0.01) were identified.  
Van der Schee et al (26) examined eNose results for the prediction of steroid 
responsiveness, reporting an AUROC of 0.88 and greater accuracy than either sputum 
eosinophil count or FeNO. For the differentiation of mild from severe asthma Dragoneiri 
et al (18) report a CVV of only 65% (M-distance, 1.23). Similarly Fens et al (31) report 
an accuracy of just 58% (AUROC 0.68) for the differentiation of fixed and classic asthma.  
Meyer et al (22) conducted a cluster analysis of both VOC data and clinical parameters. 
While VOC profiles were able to differentiate between some clinical clusters with good 
levels of accuracy, they also reported distinct clinical clusters with similar VOC profiles, 
and distinct VOC clusters with similar clinical characteristics.  
3.2.3 Loss of asthma control 
Four of the included studies examined some aspect of asthma control. Brinkman et al 
(32) conducted a prospective medication-withdrawal study. Classification accuracy for 
baseline versus loss of control - as measured by the asthma control questionnaire (ACQ) 
- was 95% using an eNose and 68% by GC-MS; loss of control versus recovery was 86% 
(eNose) and 77% (GC-MS). Ibrahim et al (20) using GC-MS report an AUROC of 0.96 for 
the identification of loss of control; and Olopade et al (24) report significantly higher 
levels of pentane during exacerbation compared to recovery. It is unlikely that the 
observed differences in breath profiles are due to changes in airway calibre - Lazar et al 
(39) undertook bronchial challenge testing on participants with stable asthma and 
reported no changes associated with bronchoconstriction. 
3.2.4 Discriminant compounds 
Nine of the included studies report on compound identities (presented in table 2). A total 
of seventy six compounds were cited as significant. Of these, nine were reported in more 
than one paper - 2,4-dimethylheptane; 2,6,10-trimethyldodecane; 2,6,11-
trimethyldodecane; acetone; benzene; ethane; isoprene; phenol; and toluene - and two 
– acetone and isoprene - were reported by three studies. The models constructed by any 
given study were thus comprised of compounds largely or entirely absent from the 
models presented by other studies. Moreover, it was not always clear in which direction 




27) found it to be elevated in asthma, while Larstad et al (21) report it to be lowered. 
Despite the lack of concordance between studies, where attempts have been made to 
validate previous models the results have been positive. van der Schee (27) used five 
compounds previously linked to asthma (acetone, isoprene, carbon disulphide, toluene 
and 1-propanol) and report an AUC of 0.79-0.84 (p<0.05).  
 
Where compounds have not been identified but validation has been undertaken results 
have been similarly positive. Fens et al (31) report a phenotyping accuracy of 83-88% in 
an external validation exercise; Montuschi et al (23) validated their data in a distinct test 
set, reporting a diagnostic accuracy of 87.5%; de Vries et al (34) found the majority of 
clusters identified in their training set to be confirmed in an independent validation set; 









Table 3 – Volatile organic compounds 
Study Discriminant compounds 
identified 
Compound type Direction of difference 
in asthma group (if 
appropriate) 
Differentiated groups Differences between 
case and control 
groups 
Awano et al 
(17) 
Dimethyl sulphide  Sulfur and nitrogen 
compounds 
+ Asthma vs non-asthma Not reported 
Brinkman et al 
(32) 
Acetonitrile   
Methanol  
Bicyclo[2.2.2]octan-1-ol.4-methyl  






Control vs loss of 
control  



















Acetic acid  
























Asthma vs controls Attempts to match 
age and gender and 
disease severity. 
Differences in FEV1 % 
predicted and FVC % 
predicted. 
Ibrahim et al 
(20) 
2,6,10-trimethyldodecane  
2,6,11-trimethyldodecane   
Benzyl alcohol  
3,4-Dihydroxybenzonitrile  
2-methyldecane   
1-methyl-4-(1-
methylethylidene)cyclohexene   
Butanoic acid,2,2-dimethyl-3-oxo-









Acids & esters 
 
Ketone 
+                                             
+   








Asthma vs controls 
 
Closely matched in 
age, gender, and BMI.  
Differences in FEV1, 




Allyl methyl sulphide  
 
4-nitroso ethylester benzoic ac  
2-butyl-cyclohexanol   
5,5-Dibutylnonane   




Sulfur and nitrogen 
 
















Camphene   
1,1-Dimethylpropyl 2-
Ethylhexanoate   
2,6,10-trimethyldodecane   
7a-Isopropenyl-4,5-
dimethyloctahydroinden-4-yl) 




Cyclohexene-4-methylene   
Terpenoids 























Closely matched in 
age. Differences in 
FEV1 % predicted, FVC 
% predicted, and in 
FEV1/FVC 
Cyclopentene,1,3-dimethyl-2-(1-
methylethyl)   
2,7-dimethyl naphthalene   
3,5-dimethyl Cyclohexanol  

















Differences in age, 
FEV1 % predicted and 
FEV1/FVC 
Benzene   
Pentadecane, 1-methoxy-13-
methyl   
Heptanoic ac   
Bicyclo[3.1.0]hex-2-ene, 4-













Control vs loss of 
control 
Differences in age, 
FEV1 % predicted, FVC 






methyl/butanal, 2-methyl  
















Larstad et al 
(21) 






Asthma vs controls Differences in gender, 
weight, FEV1 % 
predicted and FVC % 
predicted. 
Meyer et al 
(22) 




1,3-dione, 4-phenyl-  
Dodecane  
Phenol   
Quinoline decahydro-  
2-Propionyloxypentadecane  




5-hexenoic acid  
Alcohol 
Aromatic 
Acids & esters 




Sulfur & nitrogen 
Acids & esters 



















Asthma vs controls Not reported 
Olopade et al  
(24) 
Pentane  Alkane + 
 
Controlled vs loss of 
control (acute) 
NA – longitudinal 
study 
Paredi et al 
(25) 
Ethane Alkane + 
(in untreated asthma) 
Steroid treated vs non-
steroid treated & 
healthy controls 
Closely matched in 
age. 
Differences in gender, 
FEV1 % predicted and 
RV/TLC % predicted 
van der Schee 
et al (27) 
Acetone    





Asthma vs controls 
 
Differences in age, 




Carbon disulphide    
Toluene                       
1-propanol 
























Not reported Control vs loss of 
control  
NA – longitudinal study 
Brinkman et 
al (76) 
Pantolactone,5                                   
Methylacetate,32                                
Methylcyclohexane,22                        
Cyclohexane-D12,50                     
Pinene,22                                       
Eucalyptol,74                          
2-methylfuran,70              
Isopropyl alcohol              
Acids & esters 


















et al (77) 
2-Undecanal Aldehyde Diurnal variation in asthma which is not present 
in healthy controls 
Closely matched in age.  
Difference in FEV1  
Mixed age group 
Couto et al 
(37, 78).  
Nonane   
2,2,4,6,6-pentamethylheptane      
Decane,     
Dodecane 
Tetradecane 











 Asthmatic vs non-
asthmatic adolescent 
swimmers.  





The majority of abstracts did not publish details on compounds of interest, only 
Brinkman et al (76), Couto et al (38), Durrington et al (77) & Fens et al (73). The 
abstract by Fens et al was not subsequently published in full. The study by Couto et al 
was, however they included study participants under the age of eighteen. They report 
that samples from asthma and healthy controls could not be separated based on distinct 
metabolites. Brinkman et al present a list of compounds found to correlate with clinical 
variables; this was a univariate analysis without the more sophisticated methods such as 
Bonferonni correction which would normally be applied to a large dataset; moreover the 
validity of compound identification is hard to determine. While we present the 
compounds of interest for these four abstracts we draw attention to the inability to 
assess study quality, risk of bias, and full methodology. 
 
4. Discussion  
 
The accuracy of classification achieved by breathomic models suggests VOC-profiling in 
exhaled breath has potential for use in asthma diagnosis and management. The ability to 
discriminate between those with asthma and healthy controls has been consistently 
demonstrated but, to be of clinical use, these findings need to be validated in 
independent prospective cohort-studies undertaken in populations with only a clinical 
suspicion of asthma; this would enable the determination of diagnostic test accuracy. 
Given the high incidence of asthma misdiagnosis, development of such a test could be 
clinically significant and of benefit in the presence of diagnostic uncertainty.  
Sputum eosinophil count has long been considered the definitive method for assessing 
lung inflammation, and when used to guide treatment has been shown to improve 
asthma outcomes (79). However, FeNO has been found to predict steroid responsiveness 
(80) and has now been integrated into national asthma guidelines for both management 
and diagnosis (81, 82). The ease of use and rapidity of results with FeNO measuring 
devices has led to more widespread clinical uptake than that achieved by sputum 
eosinophil count. However, VOC profiling has the potential for wider application than 
either including the identification of alternative sputum profiles (such as neutrophilic or 
paucigranulocytic); monitoring of control in non-eosinophilic phenotypes; identification of 
treatable traits; and the differentiation of transient pre-school wheeze and asthma.  
A clinically-meaningful threshold has been determined for both sputum eosinophilia and 
FeNO and the reproducibility of measurements established. This is not yet the case for 
breathomic models. While VOC-measurements within-individuals may be reproducible 




been replicated or externally validated. It is important to note that, in a heterogenous 
disease such as asthma, findings based upon asthma populations defined by one ‘gold 
standard’ (such as sputum eosinophils) will not be accurately validated in a population 
based on an alternative diagnostic standard (e.g. physician diagnosed asthma) which 
may be composed of other or multiple phenotypes. 
  
The inter-study variability reported in this review may in part be due to instrument 
variability. Between-laboratory comparisons for GC-MS data can be challenging due to 
the dynamic nature of the measuring equipment. However, this may be improved 
through the implementation of the MSI reporting standards coupled with comparative 
analysis of laboratory data quality. eNoses have demonstrated variability, both between 
manufacturers (83) and between devices of the same model (84), and sensor ‘drift’ can 
be difficult to detect. This may be, to some extent, a self-limiting problem; as potential 
markers are identified, study methodology may shift from inductive to deductive. With 
targeted studies it is possible to address calibration issues from the outset giving 
increased confidence in results. 
Causes of inter-study variability do not lie exclusively with the instrumentation; 
metabolomics involves substantial inter-subject variation (62). This is not necessarily 
simply a result of comparing different asthma severities or phenotypes. A number of 
variables may have an effect on VOC profiles including the exposome (85), respiratory 
rate (86) and breathing route (87). In a study of healthy volunteers Philips et al (88) 
report the mean number of VOCs per breath sample to be <350 but the number of 
different compounds across their studies as a whole to be >3,400. Moreover, of the total 
compounds identified in their study only 27 were found in the samples of all participants. 
However, both Fens (19) and de Vries et al (29) report a high correlation coefficient for 
within-day repeatability and between-day repeatability for participants. It would seem 
then that breath prints are relatively stable within- but vary considerably between-
individuals (50). Intra-individual variability secondary to asthma activity offers the 
opportunity for  identification of disease biomarkers; and while inter-individual variability 
complicates the independent validation of results,  Sterk argues this variation offers 
hope in terms of individual phenotyping (89) including the identification of treatable 
traits and implementation of personalized medicine.  
 
Recent work in other diseases has shown that diet and lifestyle are important cofounders 
in breath VOC analysis (90). While this may apply to many of the smaller studies 
included within this review, with sufficiently large patient cohorts this may not be the 




including age and smoking - appeared not to effect the ability of a diagnostic model to 
distinguish gastric cancer from healthy controls (91).  
 
While studies have examined response to treatment in terms of identifying phenotypes 
such as ‘steroid-responsive’, there has been little published on the effect of therapy on 
exhaled VOC. Brinkman et al (92) report statistically significant correlations between 
exhaled VOC and medication metabolites as detected in urine, suggesting that exhaled 
VOC may offer a potential route for assessing therapeutic drug use. Further study of this 
area could have useful clinical application in the weaning of therapeutics.  
 
Breathomic data sets are complex and the statistical approaches used in their analysis 
have developed over time as interest in the field has grown; their evolution is likely to 
continue as wider developments in metabolomics are applied to the field of breath 
research. The majority of studies published the results of principal component analyses 
with compound loadings or receiver operating characteristic curves with accuracy 
percentages; rarely were values such as the Cox & Snell R2 published. The mean and 
standard deviation for individual compounds were also infrequently reported. Were such 
data to be made available, power calculations to determine sample sizes required to 
detect significant differences would be possible for attempts at the validation of 
individual biomarkers or prior models. 
 
In common with other emergent fields of study (94) there is a conflict between 
innovation and standardisation. Due to its potential for both inductive and deductive 
approaches, and for both offline and online analysis, breathomics is likely to remain 
more heterogenous in its methodology than some other fields. However, the arrival of 
technical standards for exhaled biomarkers (49), minimum reporting standards (72) and 
CE-marked, production-line breath capture devices, goes a long way towards addressing 
some of the potential sources of confounding and variation. Despite the publication of 
such standards there is still considerable leeway in how samples may be processed and 
analysed; these decisions are crucial given that the clinical relevance and wider 
acceptance of results hinges on the correct selection and application of these techniques. 
The quality of analysis amongst the included papers is inconsistent and hampered by the 
low numbers of participants in many of the early studies. Internal validation of results 
does seem however to be becoming the norm, and as participant cohorts continue to 
grow the risk of overfitting diagnostic models will further reduce. Whilst the 
determination of which features within a dataset should be included in diagnostic models 
has improved, compound identification remains relatively poor with few of the studies 




allow the biological origins of exhaled VOCs to be determined; the first step in linking 




Breathomics is well suited to the age of personalised medicine; the large data sets 
typically produced are highly individualised and reflect a multitude of metabolomic 
pathways; a feature which is particularly attractive for the study of complex 
heterogenous diseases such as asthma. The potential exists not only for diagnostics, 
phenotyping and the identification of treatable traits but – when coupled with other 
‘omics – the linking of phenotypes to endotypes. Results to-date are promising but 
validation in independent prospective cohorts is needed; this may be challenging given 
the high levels of inter-individual variation. However, addressing inter-study variation 
through the identification of important confounders, increasing study size, and 
methodological and analytical standardisation will facilitate these efforts. Identification of 
a limited number of compounds with strong discriminative ability may decrease 
processing time and aid the development of point of care testing; crucial if breathomics 
is to make the leap into clinical application.  
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Table A1 Example search string - PubMed 
Table A2 Research methods 1 – breath sampling methodologies 
Table A3 Abstracts – studies identified and results 
Table A4 Quality assessment – CASP tool 
Table A5 Research methods 2 – statistical methods 
 
 




(("Breath Tests"[Mesh] OR "Exhalation"[Mesh] OR "exhaled"[All Fields] OR breath[All 
Fields]) AND ("Asthma"[Mesh] OR "asthma"[All Fields] OR "asthmatic"[All Fields]) AND 
("Volatile Organic Compounds"[Mesh] OR "Volatile Organic Compound*"[All Fields])) OR 
(("asthma"[MeSH Terms] OR "asthma"[All Fields] OR "asthmatic"[All Fields]) AND 
(Breathomic*[All Fields] OR ("metabolomics"[MeSH Terms] AND ("exhalation"[MeSH 
Terms] OR "exhalation"[All Fields] OR "exhaled"[All Fields] OR breath[All Fields] OR "breath 
tests"[MeSH Terms])))) 
 





Table A2 – Research Methods: Breath Sampling  
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Monitoring of Loss of Control and 
Clinical Recovery in Asthma 
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2007 An electronic nose in the 
discrimination of patients with 
asthma and controls 
Y Y Tedlar bag 
 




2018 Exhaled breath profiling by 
electronic nose enabled 
discrimination of allergic rhinitis and 
extrinsic asthma 
N Y Tedlar bag 
 
N Y Y eNose 
Fens et al 
(19)  
2009 Exhaled breath profiling enables 
discrimination of chronic 
obstructive pulmonary disease 
and asthma 
        Y Y  Tedlar bag N   Y X eNose 
Fens et al 
(31)       
2011 External validation of exhaled breath 
profiling using an electronic nose in 
the discrimination of asthma with 
fixed airways obstruction and 
chronic obstructive pulmonary 
disease. 
Y Y Tedlar bag N Y Y eNose 
Ibrahim et 
al  (20) 
2011 Non-invasive phenotyping using 
exhaled volatile organic compounds 
in asthma 






2007 Determination of ethan, pentane 
and isporene in exhaled air – effects 
of breath-holding, flow rate and 
purified air. 
Y Y Tedlar bag Y X X GC 
Lazar et al 
(39) 
2010 Electronic Nose Breathprints are 
independent of acute changes in 
airway caliber in asthma 
Y Y Tedlar bag N X X eNose 
Meyer et al 
(22) 
2014 Defining adult asthma endotypes by 
clinical features and patterns of 
volatile organic compounds in 
exhaled air. 
N N Tedlar bag Y X X GC-MS 
Montuschi 
et al (23) 
2010 Diagnostic performance of an 
electronic nose, fractional exhaled 
nitric oxide, and lung function 
testing in asthma. 






al (24)  
1997 Exhaled pentane levels in acute 
asthma 
 
Y N Tedlar bag N X X GC 
Paredi et al 
(25) 
2000 Elevation of Exhaled Ethane 
Concentration in Asthma 
Y N Tedlar bag N X X GC 
Plaza et al  
(33) 
2015 Inflammatory asthma phenotype 
discrimination using an electronic 
nose breath analyzer 
N Y Tedlar bag N Y X eNose 
Reynolds et 
al (35)  
2014 Analysis of human breath samples 
using a modified thermal 
desorption: gas chromatography 
electrospray ionization interface 
? Y ? Y X X TD-SESI-MS 
van der 
Schee et al 
(26)  
2013 Predicting steroid responsiveness in 
patients with asthma using exhaled 
breath profiling. Clinical And 
Experimental Allergy 
N Y Tedlar bag N Y X eNose 
van der 2012 Effect of transportation and storage 
using sorbent tubes of exhaled 





Schee et al 
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breath samples on diagnostic 





2012 Detection of gastro-oesophageal 
reflux disease (GORD in patients 
with obstructive lung disease using 
exhaled breath profiling. 
N N Tedlar bag N Y X eNose 
de Vries et 
al (29) 
2015 Integration of electronic nose 
technology with spirometry: 
validation of a new approach for 
exhaled breath analysis 
Y N X N Y X eNose 
de Vries et 
al (34) 
2018 Clinical and inflammatory 
phenotyping by breathomics in 
chronic airway diseases irrespective 
of the diagnostic label 
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- 3 studies 
 
GC-MS / GC /  
TD-SESI-MS = 7 
eNose = 9 





GC-MS: Gas chromatography-mass spectrometry 





Table A3 – Research methods: Statistical Analysis 
 





Validation of gas chromatograms. In-house Univariate analysis chi-square and ANOVA; multivariate logistic regression. 
Brinkman 
et al (32) 
De-noising, peak detection & alignment, using 
XCMS. PCA, BoxCox power transformation, 
normalisation. 
NIST Univariate analysis; ANCOVA and Pearson correlation tests; FDR correction and standardised QR 
decomposition used. Multivariate analysis by PCA. T-test. 
Dragonieri 
et al (18) 
Savitzky-Golay filtering & baseline correction NA 
 
PCA & double cross-validatory implementation of linear canonical discriminant analysis. Pattern 
recognition algorithm & cross-validation estimate of error made. 
Dragonieri 
et al (30) 
?  NA PCA, independent t-test, CDA, leave-one-out cross-validation, ROC-curve 
Fens et al 
(19) 




Linear canonical discriminant analysis & ROC. Cross-validation by leave one out method. Altman 
analysis with Bonferroni correction. Intra-class correlation coefficients.  
Fens et al 
(31) 
eNose sensor data reduced by PCA NA 
  






? Univariate logistic regression analysis, PCA, multivariate logistic regression. Discriminant function 
analysis with leave-one-out cross validation. 
Larstad et 
al (21) 
? In-house  Kruskal-wallis, Wilcoxon signed rank test. 
Lazar et al 
(39) 
Savitzky-Golay filtering and baseline correction, 
sensor data reduced by PCA 
NA 
 
Mixed model analysis, paired T-tests.  
Meyer et 
al (22) 
Baseline correction, peak detection, normalisation 
of retention times, global normalisation. 
? Unsupervised hierarchical 2-step cluster analysis. Linear discriminant analysis. 
Montuschi 
et al (23) 
? ? eNose sensor data reduced by PCA. Feed-forward neural network. Unpaired t test, Mann 
Whitney U test, Pearson coefficient. 
Olopade et 
al  (24) 
? ? Wilcoxon signed rank test. 
Paredi et 
al (25) 




Plaza et al 
(33) 
? NA PCA, univariate ANOVA, post-hoc least significant difference test. Linear canonical discriminant 
analysis. Leave-one-out validation. AUROC. 
Reynolds 
et al (35) 
Noise reduction, normalisation ? Qualitative analysis of spectograms 
Van der 
Schee et al 
(26)  
eNose sensor data reduced by PCA 
 
NA Unpaired T-test, canonical discriminant analysis, cross validation by boot strapping. ROC and 
AUC. Pearson correlation coefficients. 
Van der 
Schee et al 
(27) 
Deconvolution, peak determination & peak 
alignment, background subtraction.  
NIST Principal component reduction, unpaired t-test, leave-one-out cross-validated linear canonical 




 eNose sensor data reduced by PCA NA Canonical modelling. Cross-validation, interclass Mahalanobis distance.  
 
de Vries et 
al (29) 
Corrected for ambient VOCs; normalized NA PCA, univariate ANOVA, internal validation by bootstrapping, linear canonical discriminant 
analysis, AUROC. 
De Vries et 
al (34) 
Corrected for ambient VOCs (based on alveolar 
gradient), data normalised. 
NA PCA, unsupervised heirachical clustering using Euclidean distance and ward linkage. Similarity 
profile analysis. 10x algorithm repetition upon sub-sets. Between-cluster comparisons by 
ANOVA, Kruskal-Wallis or Chi-squared tests. Validated using independent data set. Supervised 
analysis by multiple linear regression, Regression model validated using independent data set. 
 
? = not reported             ANOVA: analysis of variance 
AUC: area under curve        AUROC: Area under a receiver operating characteristic curve 
COW: Correlation optimized warping       GC x GCMS: 2 dimensional gas chromatography mass spectrometry 
HP-SPME/GC-qMS: Headspace solid-phase extraction, gas chromatography quadrupole mass spectrometry MCCV – Monte Carlo Cross Validation                                     
NIST: National Institute of Standards and Technology      PCA: Principal component analysis                           
PLSDA: partial least squares discriminant analysis      ROC: Receiver operator characteristics                                                 
SPLS: sparse partial least square discriminant analysis      SPME: Solid phase microextraction                                                           
TD-SESI-ToFMS: thermal desorption / secondary electrospray ionisation / time-of-flight mass spectrometry TIC: Total Ion Chromatogram                                                
ToFMS: Time-of-flight mass spectrometry       WEKA: a suite of machine learning software / algorithms hosted by the University of Waika   




Table A4 – Results: abstracts 
 




al (95)  
2014 Electronic noses capture severe asthma 





n = 77 
 
Significant between-cluster differences in clinical 
characteristic reported but p values not cited. 
Brinkman et 
al (96) 
2013 Unbiased cluster analysis of severe 
asthma based on metabolomics by the U-






n = 57 
p-values for between-cluster differences in 
clinical characteristics 0.001 – 0.02 
Brinkman et 
al (97) 
2015 Unbiased clustering of severe asthma 





Severe asthma n= 35 
 
p-values for between-cluster differences in 
clinical characteristics and eNose profiles 
P = 0.02-0.04 
Brinkman et 
al (98) 
2015 Exhaled breath volatile organic 
compounds can classify asthma patients 





n = 27 
Identifying sputum eosinophilia; 
AUROC 0.94  (95% CI, 0.85-1) 
Brinkman et 
al (99) 
2015 Longitudinal changes in exhaled breath 
GC/MS profiles during loss of asthma 







Subsequently published in full (32) 
(see table 1) 
Brinkman et 
al (76) 
2016 Identification of exhaled volatile organic 







2016 Identifying biomarkers of loss of 







2018 Exhaled volatile organic compounds as 
markers for medication use in asthma 





n = 108  
 
Identification of urinary oral corticosteroids 
(baseline, replication and validation) AUROCs 67 
- 91; identification of urinary salbutamol AUROCs 
70 – 82. 
Capuano et 2012 Classification ability of two eletronic 
noses in asthma and COPD 
European 
Respiratory Society 




al (101) Congress COPD n = 9 
Healthy controls n = 6 
Cyranose 320 = 92%, Ten2010 = 86% 
Classification disease vs controls: 
Cyranose 320 = 88%, Ten2010 = 88% 
Crespo et al 
(102)  
2013 Discrimination of bronchial inflammatory 
phenotype of asthmatic patients by using 




Asthma n = 44 
(eosinophilic = 16  
neutrophilic = 8  
paucigranulocytic = 20) 
Eosinophilic vs neutrophilic = 100% 
Eosinophilic vs paucigranulocytic = 100% 










An 'omics' study to investigate the 






Moderate atopic asthma = 
10 
Healthy control = 10 
Significant diurnal variability in 7 VOCs including 
2-undecanal (p=0.03) found in those with 
asthma but not controls. 
Fens et al 
(103) 
2011 Exhaled molecular patterns change after 




Mild intermittent n = 9 
Healthy controls = 14 
Before and after RV16 inoculation 
Significant change in principal components in 
asthmatics P=0.1 p=0.15. 
No change in controls 
Fens et al 
(73) 
2015 Volatile organic compounds (VOCs) in 
exhaled breath of asthma patients differ 
between loss of control and stable phase 
American Thoracic 
Society Conference 




2013 An electronic nose can distinguish 




Eosinophilic = 9 
Non-eosinophilic = 11 
Controls = 10 
Eosinophilic vs non-eosinophilic p < 0.0001 
AUROC 1.0 (95% CI – 0.96 – 1.0); CVV 59.1% 
 
Ibrahim et al 
(105) 
2010 Metabolomics of breath volatile organic 
compounds for the diagnosis and 





Subsequently published in full (20) 
(see table 1) 
Meyer et al 
(106) 
2012 Defining adult asthma endophenotypes 
by clinical features and patterns of 
volatile organic compounds in exhaled air 
European Academy 




Subsequently published in full (22)  
(see table 1) 
Montuschi 
et al (107) 
2010 Diagnostic performance of an electronic 
nose, fractional exhaled nitric oxide and 
lung function testing 
American Thoracic 
Society Conference 
Subsequently published in full (23) 
(see table 1) 




(108) with SPME-GC-MS analysis of exhaled air 
volatile organic compounds 
Respiratory Society 
Congress 
Healthy controls = 42 
 
(sensitivity 95.6%, specificity 95.8%) 
Santini et al 
(109) 
2014 Discrimination between oral 
corticosteroid-treated and oral 
corticosteroid-non-treated severe asthma 





Severe asthma (adult) = 73 
OCS vs no OCS: accuracy 71% 
 
Santini et al 
(110) 
2015 Breathomics can differentiate between 






Severe = 39 
Omalizumab vs non-use 
eNose: accuracy 0.85 
GCMS: accuracy 0.83 
van der 
Schee et al 
(111) 
2012 Predicting steroid responsiveness in 




Subsequently published in full (26) 
(see table 1)  
Schleich et 
al (112) 
2015 Do volatile organic compounds (VOCs) 
discriminate between eosinophilic and 




Asthma n= 276 
(eosinophilic = 122                 
neutrophilic = 50                                 
paucigranulocytic = 90) 
Identification of good discriminatory VOCs 
reported.  
Identity of VOCs and accuracy results not 
reported. 
de Vries et 
al (113) 
2016 Exhaled breath analysis for identifying 
eosinophilic and neutrophilic 
inflammation in a mixed population of 




Subsequently published in full (34) 
(see table 1) 
De Vries et 
al (114) 
2017 Inflammatory phenotyping of chronic 
airway disease (including both Asthma 
and COPD) by breathomics 
American Thoracic 
Society 
Subsequently published in full (34) 
(see table 1) 
Wagener et 
al (115) 
2012 Exhaled air volatile organic compounds 






n = 36 
Mod-to-severe 
 
Correlation coefficients -  
VOCs & sputum eosinophilia (>3%): 0.42-0.47  
VOCs & sputum eosinophilia (excl. participants 
on OCS): 0.49-0.62 
Wagener et 
al (116) 
2013 Exhaled breath profiling and eosinophilic 
airway inflammation in asthma – results 




N = 27 
(25 severe) 
Eosinophilic vs non-eosinophilic  
Accuracy = 85%. AUROC 99% (95% CI 0.97-1.0). 
Zanella et al 
(117) 
2018 Breath print for asthma phenotyping ? n = 245 
 
Eosinophilic, neutrophilic, paucigranulocytic, 






Mixed age population (adolescents) 
Couto et al  
Abstract 
(37)  









Oxidative stress in asthmatic and non-
asthmatic adolescent swimmers - A 
breathomics approach 
Paediatric Allergy & 
Immunology 
 
Congress of the 
European Academy 
of Allergy and 
Clinical Immunology 
 No separate clustering of groups on PCA analysis 
Controls demonstrated a more varied response 
to exercise; exhibiting a more pronounced 
decrease in the studied metabolites post-
exercise. 
 
It should be noted that nine of the abstracts and one full paper (60) were produced from a single large European programme of study - U-BIOPRED. These 
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Brinkman 
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Dragonieri 
2007 (18) 
       
 
    
Dragonieri 
2018 (30) 
           
Fens 2009 
(19) 
        
 
   
Fens 2011 
(31) 
           
Ibrahim 
(20) 
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Lazar (39) 
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Meyer (22) 
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Montuschi 
(23) 










(24)    
Paredi (25) 






























    
 
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   
de Vries 
(29) 
        
 
   
de Vries 
2018 (34) 






Note: CASP checklist question 10 “Can the test be applied to your patient or population of interest?” was omitted. This question refers to resource and opportunity costs 
for test implementation not appropriate to the field of research as it currently stands. Similarly, question 12 was answered in the negative due to the hypothesis-
generating, proof-of-concept stage of the research.  
 
HIGHLIGHTS 
• The majority of published studies report breathomics capable of differentiating 
between samples from healthy controls, those with asthma, and those with other 
respiratory disease. 
• Of the seventy six volatile organic compounds cited as significant in the literature, 
nine were reported in more than one paper. 
• Validation of these findings in independent prospective cohorts is needed as the 
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